Prevention of hospital readmissions is one of the main objectives in the management of patients with heart failure (HF). Most of the models predicting readmissions are based on data extracted from hospitalized patients rather than from outpatients. Our objective was to develop a validated score predicting 1-month and 1-year risk of readmission for worsening of HF in ambulatory patients. 
Introduction
Hospital admissions for worsening of heart failure (HF) entail a huge amount of spending of medical care resources and are predictive of increased mortality risk.
1,2 Thus, health programmes addressing the management of chronic diseases pursue the prevention of hospital readmissions by establishing appropriate personalized measures for patients at risk. 3 A large number of clinical studies predicting hospitalization for worsening of HF have been reviewed in detail. 4, 5 However, these models have not yet been successfully implemented in current clinical practice. Most of the available models were constructed based on administrative and clinical data extracted from hospital records at patient discharge, thereby not fully reflecting the ambulatory clinical condition. On the other hand, many of these studies reported the overall cause of readmission rather than the specific cause of hospitalization and, quite often, they had a limited sample size and the reported study variables were not always routinely available. An ideal risk model should, among others, overcome the sample size limitations, use currently available clinical data, accommodate ongoing variations of the clinical status of outpatients with HF, be validated, and have the potential to discriminate the 'high-risk' patients who will benefit from more intensive therapies from the 'low-risk' patients who will be appropriately managed with less intensive protocols.
This study aimed to develop a validated risk score to predict short-term (1 month) and long-term (1 year) hospitalizations for worsening of HF in ambulatory patients using precise variables that are currently collected in primary care practice.
Methods

Study population
This study includes two cohorts of patients. The first one is a derivation cohort comprised of 2507 patients with chronic HF enrolled in the Spanish Network for the Study of Heart Failure (REDINSCOR registry). This is a prospective, longitudinal, multicentre study designed to assess risk predictors of cardiac mortality and readmissions in ambulatory patients with HF. 6, 7 Patients were consecutively recruited between January 2007 and January 2011 at HF clinics in 18 hospitals. Inclusion criteria were: (i) age older than 18 years; (ii) prior hospitalization for HF (>24 h) during the previous year; and (iii) the presence of at least one echocardiographic abnormality (LVEF ≤40%, LV end-diastolic diameter ≥60 mm, altered LV relaxation indicating diastolic dysfunction, or thickness of interventricular septum/LV posterior wall ≥14 mm). All patients were symptomatic (functional NYHA class II-IV) and were treated according to the established clinical guidelines. 8 Exclusion criteria were: (i) reversible acute HF; (ii) severe valvular disease amenable to surgical repair; (iii) right HF secondary to chronic cor pulmonale; or (iv) concomitant terminal disease. The validation cohort was the MUSIC (MUerte Súbita en Insuficiencia Cardíaca) study population 9 
Study variables
Data were collected using specifically designed web forms (www.redinscor.org), and quality controls were undertaken every month. We recorded the following clinical variables at study inclusion: (i) demographic and previous clinical history; (ii) case history and physical examination; (iii) chest radiography; (iv) ECG; (v) echocardiography; (vi) laboratory blood tests; and (vii) medical treatment (Appendix S1). Standard criteria were used to define each variable. Anaemia was defined as haemoglobin <120 g/L for women and <130 g/L for men. 10 The plasma levels of NT-proBNP and BNP were dichotomized for cut-off values of BNP > 43 pmol/L (> 150 ng/L) or NT-proBNP > 118 pmol/L (> 1000 ng/L), respectively. 8 The eGFR was calculated using the CKD-EPI (Chronic Kidney Disease-Epidemiology Collaboration) method. 11 Left and right ventricular HF signs were defined according to the Framingham criteria. 12 Among them, we have included paroxysmal nocturnal dyspnoea, rales, orthopnoea, and third sound gallop as left HF signs, and neck vein distension, hepatojugular reflux, bilateral ankle oedema, ascitis, and hepatomegaly as right HF signs.
Follow-up
The follow-up data were obtained from the outpatient visits or from the event reports. Patients lost to follow-up (none at 1-month and 5 at 1-year) were censored in survival analysis. The reported events were reviewed by an ad hoc committee. 6 
Statistical analysis
Continuous variables were expressed as the mean ± standard deviation (SD) or as median (interquartile range) whenever appropriate. Differences in continuous variables were tested by analysis of variance (ANOVA) or Student's t-test for independent samples. Categorical variables are presented as frequency and percentage. Differences in the categorical variables were assessed by the 2 test or by Fisher's exact test. A multivariate analysis (Fine and Gray regression model) was built to assess the influence of the different risk predictors on survival. 13 The study endpoint for all regression analyses was the date of readmission due to HF at 1 month or at 1 year of follow-up. The competing event was death over the time period. Clinical meaningful variables showing a significant level in the univariate analysis (P < 0.1) were thereafter included in the multivariate model. A backward stepwise method was used to identify independent risk predictors with P < 0.05 for the inclusion or deletion criterion. We used competing risk methodology to estimate the probability of HF readmission or death over a time period of 1 month and 1 year using the cumulative incidence function (CIF) approach. To analyse the effect of baseline predictors on the CIF, we used the Fine-Gray regression model for the subdistribution hazard. The model included only the main effects of the predictors, without any interaction term. The proportionality assumption of the models was verified using time-dependent variables. The discriminative ability of the models was assessed by the C-statistic. The internal validity of the final predictive models was tested for 500 bootstrap re-samples, using the 'pec' package by Thomas A. Gerds 14 in the R Project for Statistical Computing. The calibration of models was assessed by the corresponding plots using the same package. To calculate the risk score for 1-month or 1-year readmission, each final predictor was multiplied by its -coefficient (by 10 for 1-month follow-up and by 13 for 1-year follow-up and rounded to the nearest integer number). Therefore, the predictors of a particular patient ranged from 0 to 30. The CIF approach was used to separate populations of patients into different risk groups. Variables with >10% of missing data were not included in the models, except for BNP and NT-proBNP due to clinical relevance. A regression multiple imputation (n = 5) was applied whenever necessary. 15 -17 A two-sided P < 0.05 was considered statistically significant. All analyses were performed using SPSS (v. 21 .0) and STATA (v. 13.1) software.
External validation cohort
As the MUSIC registry did not have a 1-month follow-up visit, we used a logistic regression analysis with the prognostic variables of the Redin-SCORE model at 6-month and 1-year follow-up. Accordingly, using the fitted model, predictions for each subject were used to calculate the area under the receiver operating characteristic curve (AUC), which has been considered equivalent to the C-statistic. 18 A loss of <10% of the discriminative ability was accepted. In addition, the AUCs for both models were compared with the DeLong method 
Results
Characteristics of the study population
The REDINSCOR registry included 2507 consecutive outpatients with chronic HF followed during a median period of 3.3 years. The clinical characteristics of these patients are summarized in Table 1 . There was a predominance of males (69%), with a mean age of 66.7 years. In nearly half of the cases, the aetiology of HF was ischaemic heart disease. The mean LVEF was 35.7%, and 39.2% were in NYHA class III-IV. Preserved LVEF (≥50%) was observed in 433 patients (17.3%).
The MUSIC registry (external validation cohort) included 992 ambulatory patients with chronic HF followed during a median period of 3.6 years. As compared with the REDINSCOR cohort, patients in the MUSIC registry were younger, had fewer cardiovascular risk factors, lower incidence of coronary artery bypass (CABG) surgery, fewer right or left HF signs, and less pulmonary hypertension and mitral valve regurgitation. They also had better renal function and lower plasma levels of NT-proBNP.
Hospitalization for worsening of heart failure
Hospital readmissions for worsening of HF occurred in 78 cases (3.1%) at 1 month after inclusion and in 424 (16.9%) patients after 1 year of follow-up. The univariable and multivariable predictors of 1-month and 1-year readmission are summarized in Tables 2 and 3. The presence of Framingham left HF signs, eGFR <60 mL/min/m 2 , and BNP > 43 pmol/L (> 150 ng/L) or NT-proBNP > 118 pmol/L (> 1000 ng/L) were independent predictors for 1-month hospitalization in the multivariable analysis. In addition to these variables, a heart rate >70 b.p.m., the presence of anaemia, and a left atrial (LA) size >26 mm/m 2 were independent predictors for 1-year hospitalization.
In order to build a score able to predict the risk of HF admission for a given patient, we assigned a scale of 30 points for both a 1-month and a 1-year hospitalization based on the -coefficient of each variable ( Table 4) . This score allowed the estimation of the risk of hospitalization for worsening HF, as illustrated in Figure 1 . Indeed, the cumulative incidence function curves distinguished a low-risk and a high-risk group (<1% and >5% event rate, respectively) for 1-month HF readmission risk, and low-risk (7.8% event rate), intermediate-risk (15.6% event rate), and high-risk groups (26.1% event rate) for 1-year HF readmission.
The C-statistics for the two models were 0.72 and 0.66, respectively. In the preserved LVEF group, the C-statistics were 0.71 and 0.72. After the bootstrap sampling, these indexes were 0.71 and 0.65. The calibration plots of the Fine and Gray models showed a fairly good calibration for 1-month and 1-year HF readmission (Figure 2) 
External validation
The AUC of the model fitted on the REDINSCOR derivation sample for 1-month and 1-year HF readmission was 0.73 and 0.67, respectively. The external validation in the MUSIC cohort showed an AUC of 0.71 and 0.69 for 6-month and 1-year readmission models, respectively. Moreover, after comparing the AUCs of both models, no significant statistical differences were found (P = 0.727 for short-term risk, and P = 0.708 for long-term risk). External validation of the calibration ability of the 1-year HF readmission model is illustrated in Figure 3 as a calibration plot, where the Hosmer-Lemeshow test gave a non-significant P-value.
Discussion
Main findings
This study provides a validated new score that predicts 1-month and 1-year hospitalization for worsening of HF in ambulatory patients based on precise variables that are currently assessed in clinical practice. Moreover, the score allows discrimination between low-and high-risk patients based on a competing risk analysis. 
Previous studies
Several studies have reported predictive models of hospitalization in HF patients. 20 The benefits of identifying HF patients needing a more personalized care are fully recognized, but predictive models of HF hospitalization are far from being implemented in current clinical practice. Factors limiting the predictive power of the available studies have been recently reviewed in detail. 4, 5 Chief among the limitations are their lower C-statistic values as compared with those found in mortality models, 21, 22 and, on the other hand, hospitalization may greatly depend on quality of care and health system characteristics rather than on the patient's clinical condition itself. Moreover, the analysed variables were largely heterogeneous among the studies and were not always validated. Quite often data were extracted from retrospective administrative data 21 or from inpatient clinical registries, 22 -25 and were rarely obtained from ambulatory HF patients. Therefore, the validation and performance of these tools have not been established in outpatients. In several instances, the scores have been developed based on data from clinical trials, 26 -28 and this scenario might be far removed from real-life daily practice.
Recently, investigators from the University of Michigan have proposed the HFPSI score (Heart Failure Patient Severity Index) to predict the 6-month risk of death and/or all-cause medical hospitalization in HF outpatients. 29 Using multivariable Cox modelling in a cohort of 1536 patients, the HFPSI included blood urea nitrogen (BUN), BNP, diabetes, history of atrial fibrillation/flutter, NYHA class, and all-cause hospitalization within the 6 months. Kaplan-Meier curves distinguished between a low-risk group (8% even rate) and a high-risk group (57% Two of the former clinical prediction tools were derived from the trial Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) 28 and the Seattle Heart Failure Model. 30 The CHARM trial evaluated all-cause mortality and the combined outcome of cardiovascular death and HF hospitalization over a 2-year period, leading to a C-statistic of 0.75. The way to calculate the CHARM score is complex because it requires fulfilling up to 24 variables. On the other hand, the model does not include data on blood laboratory tests, and the study was conducted as a clinical trial with a selected non-real-life population of HF patients. Finally, the CHARM model predicts a combined event that has different clinical implications. The widely validated Seattle Heart Failure Model looked at mortality risk in ambulatory HF patients with LVEF <30%.
Likewise, investigators of the HF-ACTION trial have developed a multivariable model predicting a combined endpoint (death and all-cause admission) with a C-index of 0.63 in outpatients with chronic HF and LVEF <35%, using patient data at the time of initial presentation from this trial. 31 As potential limitations, these authors indicated: exclusion of preserved LVEF, lack of natriuretic peptide data, and no external validation. Investigators of the CORONA trial built a series of models for several outcomes, including admission for worsening of HF. They proved the incremental prognostic value of adding biomarkers such as high-sensitivity C-reactive peptide and NT-proBNP .32 All ambulatory patients from the CORONA trial had an ischaemic aetiology, and several biochemical parameters such as sodium or haemoglobin were not available. Moreover, these data were not validated in an external cohort.
Thus, nowadays there is a lack of available scores allowing the prediction of which ambulatory patients are at risk of hospitalization for worsening of HF in our current clinical practice. 
Considerations on the Redin-SCORE
The Redin-SCORE is an easy, simple tool able to stratify the short-and long-term risk of admission for worsening of HF. It only requires from three to six clinically precise variables. This score has been constructed from a large multicentre registry, with a broad spectrum of integrative information (clinical history, physical exam, ECG, blood test, echo data, treatment) that is easily available in daily clinical practice. signs, BNP, or NT-proBNP), deleterious compensatory mechanisms (heart rate), target organ damage (anaemia, eGFR), and cardiac remodelling (LA size). Moreover, the predictors found in our study have been previously reported as prognostic markers of HF outcome.
The Redin-SCORE identifies high-risk groups of HF patients prone to be admitted within the short term (>5% rate) or long term (nearly 30% rate) and has been validated in a different population of HF patients (MUSIC cohort) with a robust result. In the outpatient environment, this score should provide the opportunity to identify those patients requiring care management programmes at specific HF clinics. Home visiting programmes and specialized HF units are nowadays the most efficient means of reducing all-cause admissions (and even mortality) for chronic HF patients. 33 Although the Redin-SCORE includes a wide range of relevant variables of HF, the REDINSCOR registry did not collect specific information about co-morbidities or psychosocial factors. As mentioned in the Methods section, the MUSIC registry did not have a 1-month follow-up visit, and therefore we used a logistic regression analysis with the prognostic variables at 6-month and 1-year follow-up. Both the study and validation cohorts comprised patients from the same geographic area, and thus our model would need further validation in other countries. Finally, some admissions may be missing if they occurred in non-REDINSCOR centres. However, the Spanish Health System assigns a geographic distribution of medical resources for each patient, and thus losses will not be significant. The incidence of hospitalization for worsening of HF of ∼17% in our study was apparently low in comparison with those reported in previous publications. 4, 5 However, studies reporting higher hospitalization rates include all-cause hospitalization and often they included patients with acute rather than ambulatory chronic HF. Lastly, the percentages of second-line therapies such as CRT and defibrillators were low, so we have not been able to analyse their probable prognostic role.
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